Results 111 to 120 of about 56,774 (264)

Should We Consider Sacral Nerve Stimulation as a Treatment for Neurogenic Lower Urinary Tract Dysfunction? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims To explore the boundary of clinical use of sacral nerve stimulation (SNS) in neurogenic lower urinary tract dysfunction (NLUTD), identifying barriers to approval and early‐impact research questions. Methods This review is derived from a proposal discussion at the International Consultation on Incontinence‐Research Society in Bristol in ...
Marcus J. Drake, Mathijs de Rijk, Stefania Musco, Jalesh Panicker, Michał Późniak, Nikita Bhatt, Brigitte Schurch   +6 more
wiley   +1 more source

Predictors of Improvement in Subjective Executive Functioning Following an Internet‐Delivered Cognitive Enhancement Intervention for Adults in Remission From Depression

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Residual cognitive deficits are commonly reported by individuals in remission from depression, often affecting daily life functioning and mental health. To provide tailored and personalized cognitive enhancement interventions for this population, there is a need for a better understanding of the characteristics of those who ...
Sunniva Brurok Myklebost, Tine Nordgreen, Eivind Haga Ronold, Aleksander Heltne, Åsa Hammar   +4 more
wiley   +1 more source

Diagnosis and Management of Progressive Multiple Sclerosis

Biomedicines, 2019
Multiple sclerosis is a chronic autoimmune disease of the central nervous system that results in varying degrees of disability. Progressive multiple sclerosis, characterized by a steady increase in neurological disability independently of relapses, can ...
Gabrielle Macaron, Daniel Ontaneda
doaj   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Laquinimod in Relapsing–Remitting Multiple Sclerosis

US Neurology, 2010
Laquinimod is a novel oral immunomodulatory agent in development for the treatment of relapsing–remitting multiple sclerosis (RRMS). It is a derivative of roquinimex that was structurally altered to maximize safety and efficacy. In animal models laquinimod was far more potent than its parent compound with no apparent propensity to induce inflammatory ...
Nuhad Abou Zeid, Emily Pharr, Douglas R Jeffery   +2 more
openaire   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Soluble CD163 Levels Correlate with EDSS in Female Patients with Relapsing–Remitting Multiple Sclerosis Undergoing Teriflunomide Treatment

BioMed
Background: multiple sclerosis (MS) presentation varies depending on the location and severity of the lesions affecting different areas of the spinal cord and brain.
Mario Jerčić, Maja Rogić Vidaković, Anita Markotić, Nikolina Režić Mužinić   +3 more
doaj   +1 more source

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, EarlyView.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Inflammatory niches as spatial drivers of disease mechanisms and targets for personalized treatment

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study provides a comprehensive review of how spatial transcriptomics reveals disease‐specific inflammatory niches across multiple skin disorders, highlighting key immune–stromal, neuro–immune and metabolic interactions that were previously unappreciated in non‐spatial analyses. Abstract Disease states are increasingly recognized as being shaped by
Rundong Jiang, Zhiqin Fang, Lam C. Tsoi, Johann E. Gudjonsson   +3 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source